Phathom Pharmaceuticals

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company dedicated to transforming the treatment landscape for people suffering from acid-related gastrointestinal (GI) disorders. The company has licensed exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), which represents a novel approach to treating conditions like GERD and H. pylori infection. Their commercialized products include VOQUEZNA tablets for the treatment of heartburn associated with Non-Erosive GERD and the healing and maintenance of healing of Erosive GERD, as well as VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for the treatment of H. pylori infection. The company is headquartered in Florham Park, New Jersey, with R&D operations in Buffalo Grove, Illinois. Beyond their approved therapies, Phathom is advancing a pipeline focused on innovative treatments for other acid-related GI disorders, including Eosinophilic Esophagitis (EoE). Committed to improving patient outcomes, Phathom brings together a team of experienced GI and industry professionals with proven track records in developing and delivering groundbreaking therapies.

The company's mission centers on addressing unmet needs in gastrointestinal medicine by leveraging cutting-edge scientific research and a patient-centered approach. Phathom believes in going beyond what's expected to bring real change for patients suffering from acid-related disorders. Their work aims to disrupt the status quo of GI treatment and usher in a new era of therapeutic options. As a publicly traded company on Nasdaq under the ticker PHAT, Phathom continues to advance its clinical programs while maintaining its commitment to scientific excellence and patient care.